Your browser is no longer supported. Please, upgrade your browser.
Settings
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-5.22 Insider Own0.10% Shs Outstand61.55M Perf Week-28.62%
Market Cap9.64B Forward P/E8.84 EPS next Y17.89 Insider Trans-82.38% Shs Float58.56M Perf Month-40.21%
Income-272.50M PEG- EPS next Q-1.49 Inst Own60.70% Short Float10.47% Perf Quarter28.05%
Sales204.80M P/S47.07 EPS this Y44.90% Inst Trans21.47% Short Ratio1.31 Perf Half Y50.46%
Book/sh1.73 P/B91.39 EPS next Y413.90% ROA-45.90% Target Price253.75 Perf Year1296.64%
Cash/sh8.27 P/C19.13 EPS next 5Y0.00% ROE- 52W Range6.77 - 331.68 Perf YTD41.78%
Dividend- P/FCF194.77 EPS past 5Y5.60% ROI- 52W High-48.57% Beta1.57
Dividend %- Quick Ratio2.80 Sales past 5Y-9.50% Gross Margin- 52W Low2419.79% ATR28.19
Employees165 Current Ratio2.80 Sales Q/Q6163.40% Oper. Margin- RSI (14)37.80 Volatility13.96% 11.09%
OptionableYes Debt/Eq4.14 EPS Q/Q-332.20% Profit Margin- Rel Volume1.23 Prev Close158.10
ShortableYes LT Debt/Eq3.62 EarningsMar 01 AMC Payout- Avg Volume4.67M Price170.59
Recom2.00 SMA20-33.65% SMA50-9.24% SMA20038.09% Volume5,155,447 Change7.90%
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Mar-29-18Upgrade Seaport Global Securities Neutral → Buy $5
Mar-05-21 02:13PM  
10:01AM  
09:20AM  
06:00AM  
06:00AM  
Mar-04-21 02:32PM  
02:06PM  
10:41AM  
09:54AM  
09:19AM  
06:00AM  
Mar-03-21 02:35PM  
02:18PM  
12:37PM  
12:05PM  
08:53AM  
06:15AM  
04:32AM  
Mar-02-21 01:24PM  
11:46AM  
11:07AM  
10:40AM  
08:45AM  
08:43AM  
06:01AM  
05:15AM  
Mar-01-21 11:30PM  
07:17PM  
06:04PM  
05:48PM  
05:14PM  
04:41PM  
04:31PM  
04:28PM  
04:20PM  
04:20PM  
04:16PM  
04:06PM  
04:03PM  
04:02PM  
02:58PM  
02:30PM  
01:45PM  
12:33PM  
11:07AM  
Feb-28-21 07:00PM  
Feb-27-21 09:23AM  
Feb-26-21 05:06PM  
03:26PM  
01:46PM  
12:31PM  
12:04PM  
08:23AM  
07:17AM  
06:10AM  
Feb-25-21 02:39PM  
02:13PM  
12:40PM  
06:08AM  
Feb-24-21 04:12PM  
01:31PM  
08:15AM  
06:21AM  
02:10AM  
Feb-23-21 03:54PM  
02:05PM  
10:55AM  
10:50AM  
08:56AM  
Feb-22-21 05:23PM  
03:58PM  
10:47AM  
10:05AM  
08:01AM  
07:47AM  
07:14AM  
07:00AM  
03:29AM  
Feb-21-21 05:53AM  
Feb-20-21 06:45AM  
06:25AM  
06:08AM  
Feb-19-21 08:24PM  
05:03PM  
04:22PM  
12:43PM  
12:14PM  
08:14AM  
08:10AM  
07:25AM  
06:01AM  
05:03AM  
Feb-18-21 04:49PM  
04:02PM  
12:36PM  
11:08AM  
06:30AM  
Feb-17-21 11:40AM  
06:50AM  
06:46AM  
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Option Exercise14.822,89542,8923,170Mar 02 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Sale225.482,895652,759275Mar 02 05:37 PM
Glenn Gregory MPresident, R&DFeb 18Sale269.572,434656,1342,811Feb 18 06:59 PM
Glenn Gregory MPresident, R&DFeb 16Option Exercise13.1610,531138,5778,523Feb 18 06:55 PM
Glenn Gregory MPresident, R&DFeb 16Sale282.715,7121,614,8122,811Feb 18 06:55 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 09Sale324.5019462,953287Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Option Exercise14.733,40650,1603,309Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Sale290.463,022877,766287Feb 09 07:40 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Option Exercise18.1515,022272,72415,297Feb 03 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Sale241.5015,0223,627,789275Feb 03 05:37 PM
Trizzino JohnEVP, CMO and CBOJan 07Sale124.1750662,830287Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Option Exercise18.6313,756256,24317,694Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Sale112.0017,4071,949,522287Jan 07 07:08 PM
YOUNG JAMES FDirectorDec 31Option Exercise51.2711,000564,00011,000Jan 05 05:38 PM
DOUGLAS RICHARDDirectorDec 31Option Exercise50.001,00050,00028,500Jan 05 05:42 PM
YOUNG JAMES FDirectorDec 31Sale113.0911,0001,244,0140Jan 05 05:38 PM
Erck Stanley CPresident and CEONov 16Option Exercise37.1452,3171,942,80172,811Nov 18 06:09 PM
Erck Stanley CPresident and CEONov 16Sale90.6552,3164,742,66720,495Nov 18 06:09 PM
Erck Stanley CPresident and CEOOct 01Sale108.56221720,494Oct 01 05:39 PM
Trizzino JohnEVP, CBO and CFOSep 30Sale110.222,250248,0025,087Oct 01 05:40 PM
Erck Stanley CPresident and CEOSep 30Sale110.2312,2311,348,20020,496Oct 01 05:39 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 29Sale107.3118,0291,934,667275Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 29Sale107.0219,9492,134,8441,561Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 29Sale107.2918,3211,965,6307,337Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 29Sale107.804,112443,26732,727Sep 30 09:27 PM
Erck Stanley CPresident and CEOSep 28Option Exercise5.9550,000297,50074,606Sep 30 09:27 PM
Trizzino JohnEVP, CBO and CFOSep 28Option Exercise5.9529,600176,12053,008Sep 30 09:28 PM
Glenn Gregory MPresident, R&DSep 28Option Exercise5.9525,000148,75046,510Sep 30 09:29 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Option Exercise5.9524,750147,26243,054Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 28Sale110.3025,0002,757,45621,510Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 28Sale110.3025,0002,757,45625,658Sep 30 09:28 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Sale110.3024,7502,729,87918,304Sep 30 09:30 PM
Erck Stanley CPresident and CEOSep 28Sale110.3025,0002,757,45636,839Sep 30 09:27 PM
EVANS GARY CDirectorAug 18Option Exercise31.0210,500325,700332,479Aug 20 06:09 PM
Glenn Gregory MPresident, R&DAug 18Option Exercise33.5655,9211,876,52557,760Aug 20 06:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Option Exercise53.8246,2422,488,61346,517Aug 20 06:20 PM
MCMANUS MICHAEL A JRDirectorAug 18Option Exercise27.608,000220,80017,951Aug 20 06:22 PM
Trizzino JohnEVP, CBO and CFOAug 18Option Exercise50.9542,7882,179,98647,875Aug 20 06:25 PM
Trizzino JohnEVP, CBO and CFOAug 18Sale148.7842,7886,366,1825,087Aug 20 06:25 PM
MCMANUS MICHAEL A JRDirectorAug 18Sale146.008,0001,168,0009,951Aug 20 06:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Sale144.3346,2426,673,982275Aug 20 06:20 PM
Glenn Gregory MPresident, R&DAug 18Sale145.2055,9218,119,8601,839Aug 20 06:14 PM
EVANS GARY CDirectorAug 18Sale150.4410,5001,579,620321,979Aug 20 06:09 PM
Glenn Gregory MPresident, R&DJun 18Option Exercise42.2016,749706,80818,588Jun 22 05:29 PM
Glenn Gregory MPresident, R&DJun 18Sale59.5316,749997,1031,839Jun 22 05:29 PM
YOUNG JAMES FDirectorJun 03Buy48.831,50073,2451,500Jun 05 05:04 PM
Herrmann John A IIISVP, General CounselMay 18Option Exercise26.1912,961339,4487,774May 20 04:35 PM
Herrmann John A IIISVP, General CounselMay 18Sale49.4412,961640,792275May 20 04:35 PM